6,978 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,978 shares of the company’s stock, valued at approximately $202,000.

Several other large investors have also recently added to or reduced their stakes in GH. Manchester Capital Management LLC acquired a new stake in shares of Guardant Health in the 1st quarter valued at $57,000. Canton Hathaway LLC acquired a new position in shares of Guardant Health during the second quarter valued at $59,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health in the second quarter valued at about $71,000. EntryPoint Capital LLC acquired a new stake in Guardant Health in the first quarter worth about $75,000. Finally, Byrne Asset Management LLC acquired a new stake in Guardant Health in the second quarter worth about $77,000. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

GH has been the subject of several analyst reports. UBS Group lifted their price target on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, August 21st. The Goldman Sachs Group upped their target price on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. Craig Hallum raised their price target on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. TD Cowen lifted their price objective on Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Bank of America increased their target price on Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, July 18th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.67.

Guardant Health Price Performance

Shares of GH opened at $21.35 on Tuesday. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. The stock has a market cap of $2.61 billion, a PE ratio of -5.45 and a beta of 1.11. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04. The business has a 50-day simple moving average of $26.64 and a two-hundred day simple moving average of $25.41.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The business had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. During the same quarter last year, the firm posted ($0.67) EPS. Guardant Health’s revenue for the quarter was up 29.2% on a year-over-year basis. Analysts anticipate that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.